Physician profile
Benjamin Mark Hoffman
NPI 1417375460
$124,397.47
in general payments reported to CMS, 2019-2025
43 companies · $71K in 2025
The $71K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $204 · 2021: $1,324 · 2022: $2,250 · 2023: $1,077 · 2024: $48K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Consulting Fee: $9,325 · Travel and Lodging: $6,959 · Food and Beverage: $5,646 · Education: $60.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,420.50 |
| Consulting Fee | $9,325.00 |
| Travel and Lodging | $6,958.55 |
| Food and Beverage | $5,646.47 |
| Education | $60.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $86,369.60 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $20,839.15 | 2019-2025 | Ultomiris |
| Amgen INC. | $5,713.25 | 2021-2025 | Uplizna |
| Genentech USA, INC. | $5,565.77 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Abbvie INC. | $1,170.77 | 2021-2025 | |
| Emd Serono, INC. | $692.72 | 2020-2025 | Mavenclad |
| Biogen, INC. | $589.44 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Ucb, INC. | $400.96 | 2021-2025 | Zilbrysq, Briviact |
| Genentech, INC. | $262.60 | 2022-2025 | Ocrevus |
| Upsher-Smith Laboratories LLC | $254.98 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $240.07 | 2020-2022 | |
| Lilly USA, LLC | $238.33 | 2020-2024 | Kisunla, Amyvid |
| Horizon Therapeutics Plc | $210.99 | 2021-2023 | Uplizna |
| Banner Life Sciences, LLC | $205.53 | 2021-2022 | |
| Argenx US, INC. | $164.73 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.